The chronic gout market is expected to experience strong growth by 2034 due to the anticipated launch of new therapies. However, the development of these therapies has faced setbacks, as the US FDA has declined to approve at least one treatment for uncontrolled gout. Meanwhile, other companies, such as Crystalys Therapeutics, are making progress with their own gout treatments, including a new phase 2 trial.